IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 221 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $393,469 | -57.3% | 49,061 | -21.1% | 0.00% | -50.0% |
| Q1 2024 | $921,952 | +108.8% | 62,210 | +14.5% | 0.00% | +100.0% |
| Q4 2023 | $441,614 | +111.0% | 54,319 | +18.1% | 0.00% | 0.0% |
| Q3 2023 | $209,273 | -28.5% | 45,994 | +10.6% | 0.00% | 0.0% |
| Q2 2023 | $292,716 | +43.9% | 41,579 | +24.9% | 0.00% | 0.0% |
| Q1 2023 | $203,414 | -1.9% | 33,292 | +2.6% | 0.00% | 0.0% |
| Q4 2022 | $207,394 | -27.7% | 32,456 | +8.5% | 0.00% | 0.0% |
| Q3 2022 | $287,000 | -10.9% | 29,909 | +2.5% | 0.00% | 0.0% |
| Q2 2022 | $322,000 | +19.3% | 29,178 | +79.6% | 0.00% | 0.0% |
| Q1 2022 | $270,000 | -36.0% | 16,245 | -26.5% | 0.00% | 0.0% |
| Q4 2021 | $422,000 | -48.3% | 22,096 | -33.3% | 0.00% | -50.0% |
| Q3 2021 | $817,000 | +14.3% | 33,120 | +20.6% | 0.00% | 0.0% |
| Q2 2021 | $715,000 | +11.0% | 27,463 | +35.0% | 0.00% | 0.0% |
| Q1 2021 | $644,000 | -38.7% | 20,338 | -10.2% | 0.00% | -50.0% |
| Q4 2020 | $1,050,000 | +35.1% | 22,637 | -4.1% | 0.00% | 0.0% |
| Q3 2020 | $777,000 | +23.1% | 23,599 | +2.7% | 0.00% | +33.3% |
| Q2 2020 | $631,000 | -13.0% | 22,976 | -5.1% | 0.00% | -40.0% |
| Q1 2020 | $725,000 | -39.3% | 24,208 | -43.9% | 0.01% | -16.7% |
| Q4 2019 | $1,195,000 | +40.9% | 43,173 | -7.3% | 0.01% | +20.0% |
| Q3 2019 | $848,000 | -26.8% | 46,583 | -1.4% | 0.01% | -28.6% |
| Q2 2019 | $1,159,000 | +128.1% | 47,266 | -11.5% | 0.01% | +133.3% |
| Q1 2019 | $508,000 | +8.5% | 53,438 | +1.1% | 0.00% | 0.0% |
| Q4 2018 | $468,000 | -15.2% | 52,874 | +7.8% | 0.00% | -25.0% |
| Q3 2018 | $552,000 | -11.1% | 49,033 | +1.1% | 0.00% | 0.0% |
| Q2 2018 | $621,000 | -26.4% | 48,497 | -2.9% | 0.00% | -20.0% |
| Q1 2018 | $844,000 | +118.7% | 49,940 | +3.5% | 0.01% | +66.7% |
| Q4 2017 | $386,000 | +27.8% | 48,269 | +24.0% | 0.00% | 0.0% |
| Q3 2017 | $302,000 | +11.9% | 38,940 | +6.2% | 0.00% | 0.0% |
| Q2 2017 | $270,000 | – | 36,674 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 3,019,201 | $26,720,000 | 20.38% |
| Broadfin Capital, LLC | 5,951,153 | $52,668,000 | 6.92% |
| GREAT POINT PARTNERS LLC | 5,567,348 | $49,271,000 | 6.23% |
| Avoro Capital Advisors LLC | 10,261,039 | $90,810,000 | 5.43% |
| FRAZIER MANAGEMENT LLC | 2,188,331 | $19,367,000 | 5.00% |
| Prosight Management, LP | 1,062,500 | $9,403,000 | 4.85% |
| Perceptive Advisors | 12,241,111 | $108,333,000 | 4.12% |
| Ghost Tree Capital, LLC | 1,000,000 | $8,850,000 | 3.21% |
| QVT Financial LP | 1,021,361 | $8,696,000 | 2.84% |
| Vivo Capital, LLC | 1,600,000 | $14,160,000 | 1.81% |